174 related articles for article (PubMed ID: 32678519)
1. Molecular and clinical characterization of PARP9 in gliomas: A potential immunotherapeutic target.
Xu H; Chai S; Wang Y; Wang J; Xiao D; Li J; Xiong N
CNS Neurosci Ther; 2020 Aug; 26(8):804-814. PubMed ID: 32678519
[TBL] [Abstract][Full Text] [Related]
2. High expression of COPB2 predicts adverse outcomes: A potential therapeutic target for glioma.
Zhou Y; Wang X; Huang X; Li XD; Cheng K; Yu H; Zhou YJ; Lv P; Jiang XB
CNS Neurosci Ther; 2020 Mar; 26(3):309-318. PubMed ID: 31710183
[TBL] [Abstract][Full Text] [Related]
3. Molecular and clinical features of a potential immunotherapy target ELK3 in glioma.
Xu H; Zhang L; Gao J; Wang J; Wang Y; Xiao D; Chai S
Medicine (Baltimore); 2022 Jul; 101(30):e29544. PubMed ID: 35905257
[TBL] [Abstract][Full Text] [Related]
4. CNN3 in glioma: The prognostic factor and a potential immunotherapeutic target.
Xu H; Chai SS; Lv P; Wang JJ
Medicine (Baltimore); 2021 Nov; 100(46):e27931. PubMed ID: 34797350
[TBL] [Abstract][Full Text] [Related]
5.
Qu S; Liu J; Wang H
Front Immunol; 2021; 12():648416. PubMed ID: 33889156
[TBL] [Abstract][Full Text] [Related]
6. SYT16 is a prognostic biomarker and correlated with immune infiltrates in glioma: A study based on TCGA data.
Chen J; Wang Z; Wang W; Ren S; Xue J; Zhong L; Jiang T; Wei H; Zhang C
Int Immunopharmacol; 2020 Jul; 84():106490. PubMed ID: 32289666
[TBL] [Abstract][Full Text] [Related]
7. MCM10 as a novel prognostic biomarker and its relevance to immune infiltration in gliomas.
Tian QS; Zhang Q; Huang W
Technol Health Care; 2023; 31(4):1301-1317. PubMed ID: 36872806
[TBL] [Abstract][Full Text] [Related]
8. Impact of beta-2 microglobulin expression on the survival of glioma patients via modulating the tumor immune microenvironment.
Tang F; Zhao YH; Zhang Q; Wei W; Tian SF; Li C; Yao J; Wang ZF; Li ZQ
CNS Neurosci Ther; 2021 Aug; 27(8):951-962. PubMed ID: 33960680
[TBL] [Abstract][Full Text] [Related]
9. Molecular and clinical characterization of TMEM71 expression at the transcriptional level in glioma.
Wang KY; Huang RY; Tong XZ; Zhang KN; Liu YW; Zeng F; Hu HM; Jiang T
CNS Neurosci Ther; 2019 Sep; 25(9):965-975. PubMed ID: 31180187
[TBL] [Abstract][Full Text] [Related]
10. In silico identification of the prognostic biomarkers and therapeutic targets associated with cancer stem cell characteristics of glioma.
Lvu W; Fei X; Chen C; Zhang B
Biosci Rep; 2020 Aug; 40(8):. PubMed ID: 32725165
[TBL] [Abstract][Full Text] [Related]
11. ITGB2 as a prognostic indicator and a predictive marker for immunotherapy in gliomas.
Xu H; Zhang A; Han X; Li Y; Zhang Z; Song L; Wang W; Lou M
Cancer Immunol Immunother; 2022 Mar; 71(3):645-660. PubMed ID: 34313821
[TBL] [Abstract][Full Text] [Related]
12. Deciphering the role of QPCTL in glioma progression and cancer immunotherapy.
Liu Y; Lu S; Sun Y; Wang F; Yu S; Chen X; Wu LL; Yang H; Shi Y; Zhao K
Front Immunol; 2023; 14():1166377. PubMed ID: 37063864
[TBL] [Abstract][Full Text] [Related]
13. Collagen Type III Alpha 1 chain regulated by GATA-Binding Protein 6 affects Type II IFN response and propanoate metabolism in the recurrence of lower grade glioma.
Huang R; Li Z; Zhu X; Yan P; Song D; Yin H; Hu P; Lin R; Wu S; Meng T; Zhang J; Huang Z
J Cell Mol Med; 2020 Sep; 24(18):10803-10815. PubMed ID: 32757451
[TBL] [Abstract][Full Text] [Related]
14. RGS16 promotes glioma progression and serves as a prognostic factor.
Huang R; Li G; Zhao Z; Zeng F; Zhang K; Liu Y; Wang K; Hu H
CNS Neurosci Ther; 2020 Aug; 26(8):791-803. PubMed ID: 32319728
[TBL] [Abstract][Full Text] [Related]
15. ARL3 is downregulated and acts as a prognostic biomarker in glioma.
Wang Y; Zhao W; Liu X; Guan G; Zhuang M
J Transl Med; 2019 Jun; 17(1):210. PubMed ID: 31234870
[TBL] [Abstract][Full Text] [Related]
16. Overexpression of GINS4 is associated with poor prognosis and survival in glioma patients.
Liu B; Liu Z; Wang Y; Lian X; Han Z; Cheng X; Zhu Y; Liu R; Zhao Y; Gao Y
Mol Med; 2021 Sep; 27(1):117. PubMed ID: 34556022
[TBL] [Abstract][Full Text] [Related]
17. Ferroptosis-related gene signature correlates with the tumor immune features and predicts the prognosis of glioma patients.
Hu Y; Tu Z; Lei K; Huang K; Zhu X
Biosci Rep; 2021 Dec; 41(12):. PubMed ID: 34726238
[TBL] [Abstract][Full Text] [Related]
18. Orphan nuclear receptor TLX promotes immunosuppression via its transcriptional activation of PD-L1 in glioma.
Zhou J; Pei X; Yang Y; Wang Z; Gao W; Ye R; Zhang X; Liu J; Liu Z; Yang X; Tao J; Gu C; Hu W; Chan FL; Li X; Mao J; Wu D
J Immunother Cancer; 2021 Apr; 9(4):. PubMed ID: 33858847
[TBL] [Abstract][Full Text] [Related]
19. Identification of a robust biomarker LAPTM4A for glioma based on comprehensive computational biology and experimental verification.
Ding Y; Jiang Y; Zeng H; Zhou M; Zhou X; Yu Z; Pan J; Geng X; Zhu Y; Zheng H; Huang S; Gong Y; Huang H; Xiong C; Huang D
Aging (Albany NY); 2024 Apr; 16(8):6954-6989. PubMed ID: 38613802
[TBL] [Abstract][Full Text] [Related]
20. Recurrence- and Malignant Progression-Associated Biomarkers in Low-Grade Gliomas and Their Roles in Immunotherapy.
Teng C; Zhu Y; Li Y; Dai L; Pan Z; Wanggou S; Li X
Front Immunol; 2022; 13():899710. PubMed ID: 35677036
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
